STAT3 (phospho-Ser727) Antibody
- Known as:
- STAT3 (phosphorilated-Ser727) Antibody
- Catalog number:
- abx000188
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- STAT3 (phospho-Ser727) Antibody
Related genes to: STAT3 (phospho-Ser727) Antibody
- Gene:
- STAT3 NIH gene
- Name:
- signal transducer and activator of transcription 3
- Previous symbol:
- -
- Synonyms:
- APRF
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-08
- Date modifiied:
- 2019-04-23
Related products to: STAT3 (phospho-Ser727) Antibody
Related articles to: STAT3 (phospho-Ser727) Antibody
- Decne. is a Thai traditional medicinal plant whose pharmacognostic standards, validated analytical methods, and anticancer mechanisms against triple-negative breast cancer (TNBC) remain unreported. The objective of this study was to establish a pharmacognostic monograph for leaves, validate a high performance liquid chromatography (HPLC) method for epigallocatechin (EGC) quantification, profile the extract by liquid chromatography/quadrupole time-of-flight mass spectrometry (LC-QTOF-MS), and investigate signal transducer and activator of transcription 3 (STAT3)-mediated anti-proliferative mechanisms in MDA-MB-231 TNBC cells. One authenticated and 14 commercial leaf samples were evaluated by macroscopic and microscopic examination, thin-layer chromatography fingerprinting, phytochemical screening, physicochemical analysis, validated HPLC, LC-QTOF-MS profiling, network pharmacology, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, flow cytometry, and Western blotting. Key diagnostic features included paracytic stomata, lignified fibers, and calcium oxalate crystals. Most physicochemical parameters met World Health Organization general guidelines. The HPLC method showed excellent linearity ( > 0.9995; 20-500 μg/mL); EGC content ranged from 0.20 to 11.05% w/w. LC-QTOF-MS tentatively identified 24 metabolites spanning phenolic acids, catechins, flavonoid glycosides, and terpenoids. Furthermore, network pharmacology identified STAT3 as the key hub target. extract selectively inhibited MDA-MB-231 viability (IC = 413 ± 23 μg/mL vs. IC > 800 μg/mL in MCF-10A), induced G2/M arrest, and suppressed p-STAT3 (Tyr705) and cyclin D1 expression in a dose-dependent manner. These findings integrate pharmacognostic identification, physicochemical standardization, and mechanistic evidence of STAT3 pathway modulation, collectively supporting as a phytopharmaceutical candidate for TNBC. leaves demonstrate reproducible pharmacognostic identity, consistent EGC-based chemical quality markers, and STAT3-mediated antiproliferative activity, warranting further preclinical investigation. - Source: PubMed
Publication date: 2026/08/12
Mandalika Siti NurfitrianiIleperuma Kasuni GayathriPhairoh KrittapatThanusuwannasak ThanundornNalinratana NonthanethThitikornpong Worathat - Signal Transducer and Activator of Transcription 3 (STAT3) plays a crucial role in tumor immunity. STAT3 promote angiogenesis, EMT, CD8 T cell activation and exhaustion and CD4 T cells differentiation. Simultaneously, STAT3 aberrant activation inhibits DC function. Moreover, STAT3 inducts immune evasion, making it one of the most promising targets for cancer therapy. Targeting STAT3 represents a promising potential therapeutic strategy, with several STAT3 inhibitors having advanced into clinical trials. In this review, we outline the regulatory role of STAT3 and its mediated signaling pathways in tumor immunity, summarize STAT3-based targeted therapies and combination immunotherapies. - Source: PubMed
Publication date: 2026/08/19
Bai YuxiangZhang ZiruZhang Jun - Sleep deprivation (SD) impairs cognitive function and induces hippocampal injury, yet the gut-derived mechanisms underlying these deficits remain incompletely understood. - Source: PubMed
Publication date: 2026/08/19
Jiang ZhiqiangZhang ZhuohanShi MengqiLi XiaopingZhang XuefeiLiu ChangWang YuhaoZhu JinGu ChunyanYang Zhan - Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency disorder distinguished by a triad of eczema, recurrent skin and pulmonary infections, and elevated serum IgE levels. The loss-of-function mutations in signal transducer and activator of transcription 3 () result in STAT3-HIES, which is considered the prototype form of HIES. Patients with STAT3-HIES are susceptible to and , while infection is rare, usually accompanied by multiple non-immunologic features including skeletal and connective tissue abnormalities, and the increasing risk of lymphoma. Owing to the diverse clinical manifestations of this disease and the lack of specific symptoms in its early stage, delayed diagnosis often occurs. - Source: PubMed
Publication date: 2026/08/19
Cao XiaobeiWang BoXu Yongsheng - Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) remains a major challenge in non-small cell lung cancer (NSCLC) treatment. Although ascomycin (FK520) has demonstrated some antitumor activity, its potential in overcoming osimertinib resistance has not been fully characterized. - Source: PubMed
Publication date: 2026/08/19
Zhang HongbingChen ChenWu DiLi WeitingGong HaoLiu ChaoWu HongfengZhang QuanLiu HongyuChen JunLi Yongwen